


1. Medicinal composition for prevention or therapy of inflammatory disease caused by bacterial DNA containing a quinazoline derivative represented by formula (I)



or pharmacologically acceptable salts thereof as effective component.


[In the formula,

R5, R6, R7, R8, which may be the same or different, denote a hydrogen atom or a substituent selected from the below-mentioned substituent group A, or adjacent two of R5, R6, R7, R8 together form a methylene dioxy group or -CH=CH-CH=CH- group,

R2 denotes aryl group or heteroaryl group which are substituted or unsubstituted,

n denotes 0 or 1,

X denotes the following formula (a) or (b):



[wherein

P denotes optionally branched chain 2-6C alkylene group,

R9, R10, which may be the same or different, denote respectively hydrogen atom, 1-4C alkyl group, 2-4C hydroxyalkyl group, or alkoxyalkyl group with a total of 3-6C,

Y denotes CHR11 (R11 denotes hydrogen atom, 1-4C alkyl group, hydroxy group, hydroxymethyl group, methoxycarbonyl group, or ethoxycarbonyl group), oxygen atom, sulphur atom or NR12 (R12 denotes hydrogen atom, 1-4C alkyl group, or aryl group which may be substituted by substituent selected from the below-mentioned substituent group A).

Z denotes hydrogen atom or hydroxy group when Y is CHR11, and Z denotes hydrogen atom when Y is oxygen atom, sulphur atom or NR12]

Substituent group (A): 1-4C alkyl group, halogen atom, hydroxy group, 1-4C alkoxy group, 1-4C

acyloxy group, -NR13R14 (R13 and R14, which may be the same or different, respectively denote hydrogen atom or 1-4C alkyl group), -NHCOR15 (R15 denotes hydrogen atom or 1-4C alkyl group), phenyl group, phenoxy group, cyano group, 1-4C acyl group, carboxy group, 2-5C alkoxy carbonyl group, carbamoyl group, N-alkyl carbamoyl (the number of carbon atoms in the alkyl group is 1-4), N,N-dialkyl carbamoyl group (the number of carbon atoms in the alkyl group may be the same or different and is 1-4)].

2. Medicinal composition in accordance with Claim 1, wherein in formula (I), at least one of R5, R6, R7, R8 is 1-4C alkyl group, 1-4C alkoxy group or amino group, or adjacent two of R5, R6, R7, R8 together form methylene dioxy group.


3. Medicinal composition in accordance with Claim 1 or 2, wherein in formula (I), R2 is phenyl group, naphthyl group, pyridyl group, thienyl group, quinolyl group or benzofuryl group, optionally substituted by substituent selected from aforementioned substituent group (A).

4. Medicinal composition in accordance with any one of Claims 1-3, wherein in formula (I), R2 is phenyl group or naphthyl group, optionally substituted by substituent selected from aforementioned substituent group (A).

5. Medicinal composition in accordance with any one of Claims 1-4, wherein in formula (I), X is denoted by formula (a), R9 and R10, which may be the same or different, respectively denote hydrogen atom, 1-4C alkyl group, 2-4C hydroxyalkyl group, or alkoxyalkyl group with a total of 3-6C.

6. Medicinal composition in accordance with any one of Claims 1-4, wherein in formula (I), X is denoted by formula (b), Y denotes CHR11 (R11 denotes hydrogen atom, 1-4C alkyl group, hydroxy group, hydroxymethyl group, methoxycarbonyl group, or ethoxycarbonyl group), oxygen atom, sulphur atom or NR12 (R12 denotes hydrogen atom, 1-4C alkyl group, or aryl group which may be substituted by substituent selected from aforementioned substituent group A).

7. Quinoline derivative represented by formula (II) or pharmacologically acceptable salt thereof.




[wherein,

R6, R7 denote respectively hydrogen atom or a group selected from aforementioned substituent group (A), or R6 and R7 together form a methylene dioxy group or -CH=CH-CH=CH- group; however, they are not both simultaneously hydrogen atoms,

R2 denotes aryl group or heteroaryl group which are substituted or unsubstituted,

n denotes 0 or 1,

X denotes the following formula (c) or (d):



[wherein

m denotes an integer of 3-6,

R9, R10, which may be the same or different, denote respectively hydrogen atom, 1-4C alkyl group, 2-4C hydroxyalkyl group, or alkoxyalkyl group with a total of 3-6C,

Y denotes CHR11 (R11 denotes hydrogen atom, 1-4C alkyl group, hydroxy group, hydroxymethyl group, methoxycarbonyl group, or ethoxycarbonyl group), oxygen atom, sulphur atom or NR12 (R12 denotes hydrogen atom, 1-4C alkyl group, or aryl group which may be substituted by substituent selected from the aforementioned substituent group A),

Z denotes hydrogen atom or hydroxy group when Y is CHR11, and Z denotes hydrogen atom when Y is oxygen atom, sulphur atom or NR12]].

8. A compound in accordance with Claim 7, wherein, in formula (II), at least one of R6 and R7 is 1-4C alkyl group, 1-4C alkoxy group or amino group, or R6 and R7 together form a methylene dioxy group.

9. A compound in accordance with Claim 7 or 8, wherein, in formula (II), R2 is phenyl group,

naphthyl group, pyridyl group, thiaryl group, quinolyl group or benzofuryl group, optionally substituted by substituent selected from aforementioned substituent group (A).

10. A compound in accordance with any one of Claims 7-9, wherein, in formula (II), R2 is phenyl group or naphthyl group, optionally substituted by substituent selected from aforementioned substituent group (A).

11. A compound in accordance with any one of Claims 7-10, wherein, in formula (II), X is denoted by formula (c), R9 and R10, which may be the same or different, respectively denote hydrogen atom, 1-4C alkyl group, 2-4C hydroxyalkyl group, or alkoxyalkyl group with a total of 3-6C.

12. A compound in accordance with any one of Claims 7-10, wherein, in formula (II), X is denoted by formula (d), Y denotes CHR11 (R11 denotes hydrogen atom, 1-4C alkyl group, hydroxy group, hydroxymethyl group, methoxycarbonyl group, or ethoxycarbonyl group), oxygen atom, sulphur atom or NR12 (R12 denotes hydrogen atom, 1-4C alkyl group, or aryl group which may be substituted by substituent selected from aforementioned substituent group A).

13. Medicinal composition which contains a compound in accordance with any of Claims 7-12 as an effective component.

14. Medicinal composition for the prevention or treatment of autoimmune disease which contains a compound in accordance with any of Claims 7-12 as an effective component.

15. Medicinal composition for the prevention or treatment of a disease caused by excess production of TNF- α or IL-6 which contains a compound in accordance with any of Claims 7-12 as an effective component.

Rising Sun Communications Ltd. Terms and Conditions (Abbreviated)

Rising Sun Communications Ltd. shall not in any circumstances be liable or responsible for the accuracy or completeness of any translation unless such an undertaking has been given and authorised by Rising Sun Communications Ltd. in writing beforehand. More particularly, Rising Sun Communications Ltd. shall not in any circumstances be liable for any direct, indirect, consequential or financial loss or loss of profit resulting directly or indirectly from the use of any translation or consultation services by the customer.

Rising Sun Communications Ltd. retains the copyright to all of its' translation products unless expressly agreed in writing to the contrary. The original buyer is permitted to reproduce copies of a translation for their own corporate use at the site of purchase, however publication in written or electronic format for resale or other dissemination to a wider audience is strictly forbidden unless by prior written agreement.

The Full Terms and Conditions of Business of Rising Sun Communications may be found at the web site address <http://www.risingsun.co.uk/Terms_of_business.html>